The agreement, which is scheduled to take effect on June 1, 2008, grants Pinnacle Biologics exclusive Ethyol or amifostine marketing authorization, certain licenses and distribution rights in Western Europe, Turkey and Israel.
Guillermo Herrera, chairman of the board of Pinnacle, said: “Our extensive international industry experience and knowledge will potentially allow MedImmune to maximize the revenue potential of Ethyol in Europe.”